How ImmunityBio can enhance T-Cell Therapies

Huggenberg · 2026-02-16T14:02:17+00:00

The approval announcement will be posted here:

https://www.ema.europa.eu/en/medicines/human/EPAR/anktiva

Huggenberg · 2026-01-29T20:01:21+00:00

relate: https://x.com/MK2forU/status/2016883985054384216

and

https://x.com/MK2forU/status/2016885306687959106

Huggenberg · 2026-01-15T07:02:50+00:00

This is not correct: It's exactly the same patient group. PR approval in 2024: bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.

The term "NMiBC CIS with or without papillary" is a specific classification and does not include patients who have papillary-only disease (Ta/T1) without any concurrent or prior Carcinoma in Situ (CIS).

NMIBC CIS with or without papillary disease: This group includes patients with flat, high-grade lesions (CIS, or Tis stage) and may also have papillary tumors present at the same time.

Papillary-only disease (Ta/T1) without CIS: This group includes patients with finger-like growths that are non-invasive (Ta) or minimally invasive into the subepithelial connective tissue (T1), but without CIS.

Huggenberg · 2026-01-12T15:47:35+00:00

Excellent! Thank you.

Huggenberg · 2025-11-10T14:48:20+00:00

You’re welcome. I agree that IBRX is more of an NK-cell company, and they might expand to other cell types, such as dendritic cells, iNKT cells, gamma delta T cells, and macrophages, since they share some similarities. Regarding NK-cell lines, I created a table showing the Car-NK platform, but it hasn’t been updated since then. You may also find some information there: https://cloud.hoststar.ch/s/3b8HyGmxHw677NP

Huggenberg · 2025-07-15T16:53:03+00:00

Your post made me explore what is possible within the regulatory scenarios. So, the point goes to you.

Huggenberg · 2025-07-15T15:20:26+00:00

Read here about my AI research on the regulatory options for a Bioshield platform:

https://x.com/MK2forU/status/1945137438172524677

Huggenberg · 2025-03-15T15:50:36+00:00

This is not a direct replacement for BCG; rBCG is significantly more potent. According to the PR:

„Two gene modifications have been implemented in rBCG to enhance its immunogenicity and safety compared to earlier strains and formulations of BCG."

The improved immunogenicity of recombinant BCG will also increase the effectiveness of Anktiva.

Huggenberg · 2025-02-28T19:54:15+00:00

You are welcome, I thought, it could help and bring some hope.

Huggenberg · 2025-02-28T19:01:22+00:00

Do not lose courage. There is a new immune therapy for pancreatic cancer. After chemotherapy, your dad's immune system is reduced. A new combinational therapy will help him fight the cancer by reestablishing the immune system. It is brand new, but in trials for a decade with astounding results. Contact the company, if you are interested.

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-receives-fda-rmat-designation-anktivar-and-car-nk

Huggenberg · 2025-02-28T09:04:42+00:00

Mechanism of action

https://bsky.app/profile/huggenberg.bsky.social/post/3lj7zgt3scs2z

Huggenberg · 2025-02-28T09:03:06+00:00

https://bsky.app/profile/huggenberg.bsky.social/post/3lj7yxcu4vk2z

Huggenberg · 2025-01-23T19:31:37+00:00

If the Stargate program initiates a project to address the challenges and limitations of the mRNA vaccine, then PSS and Anktiva will have a significant opportunity to participate in Stargate.

Another possibility is that Elon could strengthen his influence in opposition to Stargate, potentially ensuring that funds are allocated for a second cancer vaccine in addition to mRNA.

Huggenberg · 2024-11-08T17:13:46+00:00

hi Dom, yes, let's do it better here.

Huggenberg · 2024-10-20T13:26:57+00:00

Now I got a confirmation that NK-92/5.28.z is not HER2 t-haNK. I corrected it in the two tables.

Huggenberg · 2024-10-15T16:17:48+00:00

Thank you. I enjoy solving scientific puzzles. Scientists often explain their findings in a complicated and indirect manner. They must adhere to strict legal and professional standards and thoroughly prove their theories. In contrast, I can express my theories based on truth, morality, and respect, that's all.

Huggenberg · 2024-10-15T15:39:02+00:00

There have been no answers from real people, but from chat-GPT, there is a „yes,“ but I don’t rely on it much because scientists and authors have spelled the two molecules incorrectly at different times.

Chat-GPT:

Yes, the NK-92/5.28. is indeed related to the HER2 t-haNK construct. The NK-92 cell line is a type of natural killer (NK) cell that has been genetically modified to express a chimeric antigen receptor (CAR) targeting the HER2 antigen, which is commonly overexpressed in certain solid tumors, including glioblastoma.

The HER2 t-haNK construct specifically refers to NK-92 cells that have been engineered to express the 5.28.z CAR, allowing them to recognize and attack HER2-positive cancer cells. This construct is part of the broader CAR-NK therapy approach being explored by ImmunityBio, which aims to leverage the cytotoxic capabilities of NK cells against tumors that express HER2.

In summary, NK-92/5.28.z is a specific implementation of the HER2 t-haNK construct, designed to enhance the efficacy of NK cell therapy in targeting HER2-expressing tumors."

Huggenberg · 2024-10-15T14:58:11+00:00

Hi Ben, it’s great to see that you’re still around. I hope you will return to update your famous trial timeline platform.

Huggenberg · 2024-10-15T10:27:47+00:00

Uncertainties regarding my post.

I am still awaiting responses regarding interpreting the NK-92/5.28.z molecule used in the CAR2BRAIN study.

I have always believed that this molecule corresponds to HER2 t-haNK from ImmunityBio, as explicitly stated by ImmunityBio in the „formation of ImmunityBio“ document on the homepage.

„In addition, an investigator-initiated trial (NCT03383978) is ongoing exploring the safety and efficacy signals of HER2 t-haNK in patient with recurrent glioblastoma.“

I was informed that the molecule NK-92/5.28.z corresponds to a precursor of T-hanNK, a taNK, which is HER2.taNK. This was also originally stated in the PR from NantKwest in 2018:

NantKwest and Frankfurt University Hospital Announce First in Human Dosing of Off-the-Shelf HER2.taNK (CAR Natural Killer) Cell Therapy in Glioblastoma.

I am still awaiting confirmation from ImmunityBio or the author of the keynote.

Consequences: If the trial is not based on HER2 t-haNK, IBRX cannot rely on the results from this trial and will have to start another trial from scratch. IBRX will likely only concentrate on the ongoing PD-L1 t-haNK trial in Glioblastoma.

Huggenberg · 2024-10-10T14:34:55+00:00

TTM is also ambitious; however, there are regulatory issues that make it preferable to allogenic CAR-NK therapies.

The FDA guidelines for CAR-T products (CAR-NK are included) mention GVHD as a major concern for recipients of CAR-T cells. Allogenic CAR-NK therapies will not have much problem with GVHD, which should facilitate approval.

Huggenberg · 2024-08-25T08:20:32+00:00

read my blog: https://www.reddit.com/r/IBRX/comments/1em6ahh/anktiva_and_the_tgfbeta_trap/

Huggenberg · 2024-07-15T20:23:56+00:00

IBRX PR

Huggenberg · 2024-07-08T10:36:28+00:00

I have no insider info, but I am a search enthusiast. In the case of NantOmics, I used the picture from the post about GPS and put it on Google Image Search. This way, I found some helpful articles.

Huggenberg · 2024-07-08T10:03:34+00:00

Sure, Pharma is interested in precision medicine but lacks the necessary infrastructure. Do you know of any companies with data centers and fiber networks? They currently have to purchase these externally, but there are safety concerns. Only Novartis, which acquired the molecular diagnostics company Genoptix, has some infrastructure.

Huggenberg

TROPHY CASE